NASDAQ:GYRE
Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc.'s revenue grew 10.2% in fiscal 2025 to $116.6M while operating margin fell to 9.9%. Free cash flow was −$180,000, −0.2% of revenue, and the diluted share count rose 0.9%.Summary generated from Gyre Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 13, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$116.6M
Revenue growth+10.2%
Revenue, 5-yr CAGR+41.0%
Gross margin95.4%
Operating margin9.9%
Net margin8.5%
ROICn/a
Return on equity11.7%
Debt / equityn/a
Free cash flow−$180,000
FCF margin−0.2%
Share count change+0.9%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 7 | 102 | 113 | 106 | 117 |
| Operating income | −88 | 9 | −67 | 16 | 11 |
| Net income | −88 | 4 | −85 | 18 | 10 |
| Free cash flow | −85 | 6 | 17 | −6 | −0 |
Recent filings
- 8-KRegulation FD disclosure
Sep 1, 2026 - 8-KRegulation FD disclosure
Aug 26, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 7, 2026 - 8-KResults of operations and financial condition
Aug 7, 2026 - 4Insider transaction report
Aug 4, 2026 - 4Insider transaction report
Aug 4, 2026 - 8-KDirector or officer change
Jul 16, 2026 - 8-K/AAmended results of operations and financial condition
Jul 15, 2026